meta|evidence COVID-19
  • Living systematic review and meta-analysis
  • ***** adjuvant therapies
  • anti-inflammatoty and immuno-therapy
  • Immunostimulants drugs
  • neutralizing antibody
  • amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)
  • bamlanivimab monotherapy
  • bamlanivimab/etesevimab
  • Bebtelovimab (LY-CoV1404)
  • bevacizumab
  • casirivimab/imdevimab (Ronapreve)
  • cilgavimab and tixagevimab (Evusheld)
  • equine polyclonal antibodies INM005
  • regdanvimab (Regkirona- CT-P59-Celltrion)
  • sotrovimab (Xevudy; VIR-7831)
  • XAV-19
  • ***** antiandrogenic
  • ***** antiviral and associated therapy
  • ***** control
  • ***** Drugs for acid related disorders
  • ***** miscellaneous
  • ***** Oral antidiabetic drugs
  • ***** Renin-angiotensin-system-acting agents
  • ***** vaccines
  • ***** Vitamins
  • COVID 19 hospitalized
  • COVID 19 all comers
  • COVID-19 mild to moderate
  • COVID-19 severe or critically
  • COVID 19 outpatients
  • COVID-19 (hospitalized or not)
  • COVID-19 prophylaxis (children)
  • COVID-19 prophylaxis (excluding children)
  • infections other than COVID-19
  • Long COVID-19
  • preventing respiratory virus transmission
  • secondary prevention